Leeds General Infirmary

Running trials

• Not yet recruiting

  Diagnosis of Women With ANOCA

  NCT07802457· Source

• Not yet recruiting

  Exercise Therapy for Women With ANOCA

  NCT07733986· Source

• Not yet recruiting

  Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)

  NCT07682129· Phase 2· Source

• Recruiting

  Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects With Reduced Ejection Fraction

  NCT07403058· Source

• Recruiting

  A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy

  NCT07287982· Phase 2· Source

• Recruiting

  A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45

  NCT07038824· Phase 1/2· Source

• Recruiting

  A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

  NCT06920004· Phase 3· Source

• Recruiting

  A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44

  NCT07037862· Phase 1/2· Source

• Active, not recruiting

  Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older

  NCT06460506· Phase 3· Source

• Recruiting

  A Multi-Arm, Platform Trial For Relapsed Neuroblastoma

  NCT07334301· Phase 1/2· Source

• Active, not recruiting

  A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis

  NCT06558279· Phase 3· Source

• Enrolling by invitation

  Angina After PCI: a Systems Medicine Study

  NCT06854302· Source

• Recruiting

  A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

  NCT06439277· Phase 3· Source

• Active, not recruiting

  A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

  NCT06298552· Phase 3· Source

• Recruiting

  Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II

  NCT06271577· Source

• Not yet recruiting

  VItamiN D treatIng Chronic heArT Failure (the Effect of Vitamin D Supplementation in Patients With Heart Failure)

  NCT03416361· Source

• Active, not recruiting

  Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure

  NCT05598333· Phase 2· Source

• Active, not recruiting

  Effects of Sedation, TEmperature and Pressure After Cardiac Arrest and REsuscitation on Major Adverse Kidney Events (STEPCARE-MAKE)

  NCT07579390· Source

• Recruiting

  IIH Intervention: A Clinical Trial Comparing 2 Treatments (Shunts and Stents) Evaluation Of Clinical Effectiveness And Cost Effectiveness

  NCT07440277· Source

• Active, not recruiting

  Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease

  NCT05701358· Source

• Recruiting

  RCT of Implantable Defibrillators in Patients With Non Ischemic Cardiomyopathy, Scar and Severe Systolic Heart Failure

  NCT05568069· Source

• Recruiting

  Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation - APOLLO-EU Trial

  NCT05496998· Source

• Recruiting

  Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

  NCT05549297· Phase 3· Source

• Active, not recruiting

  A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

  NCT05444257· Phase 3· Source

• Recruiting

  A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

  NCT05489705· Source

• Active, not recruiting

  CiproPAL (Ciprofloxacin Prophylaxis in Acute Leukaemia)

  NCT04678869· Source

• Recruiting

  FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

  NCT04625907· Phase 1/2· Source

• Recruiting

  The Early Valve Replacement in Severe ASYmptomatic Aortic Stenosis Study

  NCT04204915· Source

• Recruiting

  High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

  NCT04221035· Phase 3· Source

• Active, not recruiting

  Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

  NCT03363373· Phase 2· Source

• Active, not recruiting

  Paediatric Hepatic International Tumour Trial

  NCT03017326· Phase 3· Source

• Active, not recruiting

  The British Heart Foundation SENIOR-RITA Trial

  NCT03052036· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Heart failure6 recruiting
• Coronary artery disease4 recruiting
• Childhood cancers3 recruiting
• Duchenne muscular dystrophy3 recruiting
• Neuroblastoma2 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• High blood pressure1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Melanoma1 recruiting
• Sarcoma1 recruiting
• Spinal muscular atrophy1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack

  NCT06139328· Phase 2· Source

• Completed

  Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age

  NCT05882357· Phase 3· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Source

• Completed

  Use of a Novel SUBCUTaneous Preparation of Furosemide to Facilitate Early Supported Discharge of Patients With Heart Failure

  NCT05419115· Phase 2· Source

• Completed

  A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

  NCT05076149· Phase 3· Source

• Completed

  Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis

  NCT03593590· Source

• Completed

  Multiple Sclerosis-Simvastatin Trial 2

  NCT03387670· Phase 3· Source

• Completed

  ODYSSEY (PENTA 20)

  NCT02259127· Phase 2/3· Source